Thanks for the link.
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%
Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%
Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767
Recent LYEL News
- Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 • GlobeNewswire Inc. • 06/01/2026 12:00:00 PM
- Lyell Immunopharma Announces Participation in May Investor Conferences • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/11/2026 03:12:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:10:44 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 • GlobeNewswire Inc. • 05/06/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:06:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:05:53 PM
- Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/03/2026 08:23:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 11:26:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 11:24:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 08:50:15 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 08:16:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:12:21 PM
- Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results • GlobeNewswire Inc. • 03/12/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 12:05:17 PM
- Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Lyell Immunopharma Announces Participation in March Investor Conferences • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 01:46:32 AM
- Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma • GlobeNewswire Inc. • 02/12/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:05:21 AM
